(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 3 623 385 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71

(48) Corrigendum issued on:
06.05.2020 Bulletin 2020/19

(43) Date of publication:
18.03.2020 Bulletin 2020/12

(21) Application number: **19192268.1**

(22) Date of filing: **15.11.2012**

(51) Int Cl.:
C07K 16/28 *(2006.01)* ***A61K 39/395*** *(2006.01)*
A61P 35/02 *(2006.01)* ***A61P 37/00*** *(2006.01)*

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: **15.11.2011 US 201161560144 P**
15.11.2011 US 201161560149 P
15.11.2011 US 201161560162 P
15.11.2011 US 201161560178 P
15.11.2011 US 201161560183 P
24.05.2012 US 201261651474 P
24.05.2012 US 201261651486 P

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
12803509.4 / 2 780 374

(71) Applicants:
- **Amgen Research (Munich) GmbH**
  81477 München (DE)
- **Amgen Inc.**
  Thousand Oaks, California 91320-1799 (US)

(72) Inventors:
- **KUFER, Peter**
  81477 Munich (DE)
- **RAUM, Tobias**
  81477 Munich (DE)
- **HOFFMANN, Patrick**
  81477 Munich (DE)
- **KISCHEL, Roman**
  81477 Munich (DE)
- **LUTTERBUESE, Ralf**
  81477 Munich (DE)
- **RAU, Doris**
  81477 Munich (DE)
- **ADAM, Paul**
  55216 Ingelheim am Rhein (DE)
- **BORGES, Eric**
  55216 55216 Ingelheim am Rhein (DE)
- **HEBEIS, Barbara**
  55216 Ingelheim am Rhein (DE)
- **HIPP, Susanne**
  55216 Ingelheim am Rhein (DE)

(74) Representative: **Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB**
Ganghoferstraße 68 B
80339 München (DE)

Remarks:
This application was filed on 19-08-2019 as a divisional application to the application mentioned under INID code 62.

(54) **BINDING MOLECULES FOR BCMA AND CD3**

(57) The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

EP 3 623 385 A8

Figure A16


Treatment (Days 13-29)
Group 1: Vehicle w/o T cells (i.v.)
Group 2: Vehicle (i.v.)
Group 3: BCMA-50 x CD3 (0.5 mg/kg/d, i.v.)
Tumor Volume [mm³]
Day of experiment
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30